1. The Chinese First-Episode Schizophrenia Trial: background and study design.
- Author
-
Han X, Yuan YB, Yu X, Zhao JP, Wang CY, Lu Z, Yang FD, Dong H, Wu YF, Ungvari GS, Xiang YT, and Chiu HF
- Subjects
- Adolescent, Adult, Aripiprazole, China, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Olanzapine, Treatment Outcome, Antipsychotic Agents therapeutic use, Benzodiazepines therapeutic use, Piperazines therapeutic use, Quinolones therapeutic use, Research Design, Risperidone therapeutic use, Schizophrenia drug therapy
- Abstract
Schizophrenia is a complex illness with unknown aetiology and pathogenesis. Currently, a considerable number of patients with schizophrenia do not receive standardised and systematic treatment in China. In the past years, many controlled trials have been conducted in chronic schizophrenia. In contrast, research on first-episode schizophrenia is lacking. This paper describes the background and design of the Chinese First-Episode Schizophrenia Trial project--a multicentre, randomised, open-label clinical trial. A total of 600 first-episode schizophrenia patients were randomly divided into 3 groups and treated with risperidone, aripiprazole, and olanzapine for 1 year. During the study period, only 1 medication change of the 3 antipsychotic medications was allowed.
- Published
- 2014